• LAST PRICE
    162.5400
  • TODAY'S CHANGE (%)
    Trending Down-0.7300 (-0.4471%)
  • Bid / Lots
    160.0000/ 1
  • Ask / Lots
    166.5000/ 8
  • Open / Previous Close
    163.8200 / 163.2700
  • Day Range
    Low 161.7000
    High 165.5000
  • 52 Week Range
    Low 126.9681
    High 225.2300
  • Volume
    101,477
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 163.27
TimeVolumeBGNE
09:32 ET1380163.82
09:34 ET100162.625
09:36 ET700163.29
09:38 ET100163.355
09:39 ET100163.425
09:41 ET100163.255
09:43 ET400163.95
09:45 ET301164.05
09:48 ET100164.19
09:50 ET600164.55
09:52 ET2813165.19
09:54 ET200165
09:59 ET500165
10:10 ET600164.935
10:12 ET674164.9
10:15 ET200164.92
10:19 ET100164.83
10:21 ET300164.705
10:24 ET600164.745
10:26 ET200164.755
10:28 ET600164.54
10:30 ET700164.355
10:32 ET200164.03
10:35 ET200163.88
10:39 ET3500164.585
10:42 ET100164.64
10:46 ET300163.84
10:50 ET394163.93
10:51 ET200163.875
10:55 ET100163.98
10:57 ET165164.5899
11:02 ET1040164.185
11:06 ET100164.495
11:08 ET100163.86
11:13 ET100164.23
11:15 ET300164.16
11:24 ET300164
11:26 ET498164.025
11:27 ET200163.93
11:33 ET300163.695
11:36 ET200163.92
11:38 ET200164.03
11:42 ET5500164.08
11:45 ET100164.07
11:47 ET547164
11:49 ET100164.175
11:56 ET300164.3
11:58 ET300164.01
12:03 ET455164.3
12:07 ET100164.265
12:18 ET100164.29
12:21 ET200164.29
12:25 ET100164.24
12:34 ET100164.03
12:36 ET100164.015
12:38 ET100164.065
12:43 ET200164.06
12:45 ET700163.91
12:48 ET400164
12:57 ET750163.805
01:01 ET400163.75
01:06 ET600164
01:08 ET500164.05
01:24 ET100163.81
01:26 ET100163.915
01:30 ET500164
01:32 ET300164.13
01:35 ET527163.86
01:46 ET200164.055
01:50 ET100163.78
02:06 ET260163.7091
02:11 ET400163.74
02:26 ET100163.29
02:31 ET100163.36
02:36 ET700163.03
02:38 ET100163.17
02:44 ET100162.88
02:47 ET1116162.51
02:49 ET100162.29
02:51 ET100162.27
02:54 ET100162.48
02:56 ET300162.71
03:02 ET600162.25
03:03 ET100162.46
03:07 ET400162.39
03:14 ET100162.18
03:18 ET100162.265
03:20 ET400161.83
03:21 ET100161.94
03:23 ET100162.015
03:25 ET100162.16
03:30 ET200162.06
03:32 ET100161.98
03:34 ET400161.9
03:36 ET300161.955
03:38 ET100161.9
03:39 ET200161.73
03:41 ET100161.7
03:43 ET100161.77
03:45 ET300161.9
03:48 ET200161.95
03:50 ET615162.04
03:52 ET600162.005
03:54 ET700162
03:56 ET1305162.14
03:57 ET100162.34
03:59 ET1364162.54
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBGNE
Beigene Ltd
17.4B
-21.5x
---
United StatesBMRN
Biomarin Pharmaceutical Inc
16.3B
79.0x
---
United StatesUTHR
United Therapeutics Corp
14.9B
16.0x
+8.22%
United StatesNBIX
Neurocrine Biosciences Inc
14.7B
40.3x
+62.04%
United StatesEXAS
Exact Sciences Corp
8.9B
-34.2x
---
United StatesMEDP
Medpace Holdings Inc
11.8B
35.9x
+35.10%
As of 2024-07-26

Company Information

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact Information

Headquarters
C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
Phone
345-949-4123
Fax
---

Executives

Co-Founder, Executive Chairman of the Board, Chief Executive Officer
John Oyler
President, Chief Operating Officer, General Manager - China
Xiaobin Wu
Co-Founder, Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Aaron Rosenberg
Senior Vice President, General Counsel
Chan Lee

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$17.4B
Revenue (TTM)
$2.8B
Shares Outstanding
105.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.57
EPS
$-7.57
Book Value
$36.95
P/E Ratio
-21.5x
Price/Sales (TTM)
6.3
Price/Cash Flow (TTM)
---
Operating Margin
-26.60%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.